Segmental Reporting (Tables)

9 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Schedule of Segment Revenue from Major Products

	3 months to,	3 months to,	9 months to,	9 months to,
	September 30,	September 30,	September 30,	September 30,
	2013	2012	2013	2012
	$’M	$’M	$’M	$’M
	___________	___________	___________	___________
VYVANSE	299.2	247.1	897.9	773.3
LIALDA/MEZAVANT	141.9	104.4	379.9	288.5
ELAPRASE	129.1	110.5	392.6	358.3
REPLAGAL	108.5	121.7	336.6	379.3
VPRIV	87.8	74.9	251.9	229.3
ADDERALL XR	81.4	102.2	293.5	347.5
INTUNIV	80.8	69.0	248.9	206.6
PENTASA	70.6	67.0	215.2	196.7
FIRAZYR	62.6	30.3	153.8	81.7
FOSRENOL	51.9	38.1	136.3	126.8
XAGRID	24.2	22.0	74.1	70.7
DERMAGRAFT	23.9	33.7	64.7	134.9
Other product sales	33.0	33.6	96.4	115.5
	____________	____________	____________	____________
Total product sales	1,194.9	1,054.5	3,541.8	3,309.1
	____________	____________	____________	____________